Form 4: OptiNose Director Bednarski Reports Stock Option Changes Following Merger with Paratek Pharmaceuticals
SEC Form 4
Director Eric Bednarski reports changes in stock option holdings due to the merger between OptiNose and Paratek Pharmaceuticals, including cash consideration and contingent value rights.
Summary
- Eric Bednarski, a director of OptiNose, filed a Form 4 detailing changes in beneficial ownership following the merger of OptiNose with Paratek Pharmaceuticals on May 21, 2025.
- The merger resulted in OptiNose becoming a wholly-owned subsidiary of Paratek.
- Each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR), potentially worth up to an additional $5.00.
- Outstanding stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, with certain options being canceled or converted into CVRs depending on the exercise price.
- Bednarski's stock options with exercise prices of $15.60, $17.70, $29.25 and $24.45 were impacted by the merger agreement.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports the changes in beneficial ownership due to a merger. The value of the CVR is uncertain, adding a slight element of risk.
Negatives
- Some of Eric Bednarski's stock options were canceled for no consideration because their exercise price was greater than $14.00.
Risks
- The contingent value rights (CVRs) are subject to the achievement of specified milestones, and there is no guarantee that the full $5.00 potential value will be realized.
Future Outlook
The future value of the CVRs depends on the achievement of milestones as specified in the CVR Agreement.
Industry Context
Mergers and acquisitions are common in the pharmaceutical industry as companies seek to expand their product portfolios, pipelines, and market share. This merger allows Paratek to acquire OptiNose's assets and expertise.
Comparison to Industry Standards
- It is difficult to compare this specific transaction to industry standards without knowing the specific milestones associated with the CVRs.
- CVRs are often used in pharmaceutical M&A deals to bridge valuation gaps and align the interests of the buyer and seller around future product development or commercialization milestones.
- Comparable companies and projects would need to be assessed to determine if the $5.00 potential CVR value is reasonable given the risks and uncertainties involved.
Stakeholder Impact
- Shareholders received $9.00 in cash and a CVR for each share.
- Option holders received cash or CVRs depending on the exercise price of their options.
- Employees may experience changes as a result of the merger.
Key Dates
| Date | Description |
|---|---|
| 03/19/2025 | Issuer entered into an Agreement and Plan of Merger with Paratek Pharmaceuticals, Inc. |
| 05/21/2025 | Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger. |
| 05/21/2025 | Date of the reported transaction. |
| 06/06/2034 | Expiration date of one of the stock option grants. |
| 06/08/2033 | Expiration date of one of the stock option grants. |
| 06/08/2032 | Expiration date of one of the stock option grants. |
| 12/10/2031 | Expiration date of one of the stock option grants. |
Keywords
Merger, OptiNose, Paratek Pharmaceuticals, Stock Options, Contingent Value Right, Form 4, Beneficial Ownership, Bednarski
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.